Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor-Reference-Cited by-同舟云学术

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Published:2022-07 Issue:1 Volume:166 Page:117-125
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Tymon-Rosario Joan R.,Manara Paola,Manavella Diego D.,Bellone Stefania,Hartwich Tobias Max Philipp,Harold Justin,Yang-Hartwich Yang,Zipponi Margherita,Choi Jungmin,Jeong Kyungjo,Mutlu Levent,Yang Kevin,Altwerger Gary,Menderes Gulden,Ratner Elena,Huang Gloria S.,Clark Mitchell,Andikyan Vaagn,Azodi Masoud,Schwartz Peter E.,Alexandrov Ludmil B.,Santin Alessandro D.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference26 articles.

1. Cancer statistics, 2021;Siegel;CA Cancer J. Clin.,2021

2. Rare uterine cancer: carcinosarcomas. Review from histology to treatment;Artioli;Crit. Rev. Oncol. Hematol.,2015

3. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition;Zhao;Proc. Natl. Acad. Sci. U. S. A.,2016

4. TCGA classification of endometrial cancer: the place of carcinosarcoma;Travaglino;Pathol. Oncol. Res.,2020

5. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes;Garg;Int. J. Gynecol. Cancer,2010

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas;Gynecologic Oncology;2024-08

2. Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes;Frontiers in Oncology;2024-05-24

3. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers;Clinical Cancer Research;2024-03-27

4. Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report;Gynecologic Oncology Reports;2024-02